-- （更新：Inhibrx已回复的置评请求。） 据路透社周三援引知情人士报道，德国默克集团（Merck KGaA）和日本小野药品工业株式会社（Ono Pharmaceutical）已对Inhibrx Biosciences（INBX）的实验性抗癌药物表示出兴趣，该药物估值可能超过80亿美元。 知情人士告诉路透社，Inhibrx正在考虑联合剥离该疗法INBRX-106以及另一种实验性抗癌药物，如果临床试验成功，这两种药物的总价值可能超过90亿美元。 Inhibrx拒绝就此事向置评，而默克和小野药品工业株式会社尚未回复置评请求。 （市场动态新闻来源于与全球市场专业人士的对话。这些信息被认为是来自可靠来源，但可能包含传闻和猜测。准确性无法保证。）
Price: $112.88, Change: $+0.32, Percent Change: +0.28%
Solvar (ASX:SVR) said that the Federal Court of Australia ordered the firm's unit Money3 Loans to pay a pecuniary penalty in the sum of nearly AU$1.6 million, according to a Monday Australian bourse filing.The court's decision was in relation to the penalty payable for the contraventions of the National Consumer Credit Act during the period from 2019 to 2021."Since the period in question, Money3 has invested further in its governance, complaints, hardship, and underwriting practices," Solvar Chief Executive Scott Baldwin said.
Hangzhou Changchuan Technology (SHE:300604) posted first-quarter attributable net profit of 352.5 million yuan, up 218% from 111.0 million yuan the previous year.Earnings per share rose to 0.5472 yuan from 0.1756 yuan, according to a weekend filing with the Shenzhen bourse.Operating revenue rose 69% year over year to 1.38 billion yuan from 815.3 million yuan.Shares of the semiconductor test equipment company rose 3% in recent trade.
Dawning Information Industry's (SHA:603019) net profit attributable to shareholders in the first quarter jumped 22% to 227.8 million yuan, or 0.156 yuan per share, according to a Saturday filing on the Shanghai bourse.The supercomputer manufacturer's shares rose 2% in morning trade on Monday.Operating revenue rose 24% to 3.20 billion yuan from 2.59 billion yuan in the prior year.